Items Tagged ‘checkpoint inhibitors’

September 25th, 2017

FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns

By

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations, the FDA has added two Tecentriq (atezolizumab) clinical studies to its growing list of clinical trials placed on partial hold over safety concerns while further […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, Multiple Myeloma, News, PD-1, PD-L1


August 14th, 2017

Head and Neck Cancer-What You Need to Know

By

Head and neck cancer includes a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and mouth. Globally, head and neck cancer is the seventh most common type of cancer with an estimated 400,000-600,000 diagnoses every year. Head and neck cancers account for about 3 percent of […]

View full entry

Tags: checkpoint inhibitors, Head and Neck Cancer, human papilloma virus, keytruda, News, opdivo, PD-1, Throat Cancer


July 6th, 2017

First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients

By

Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics of their tumor, according to a new study reported by a global team led by David Carbone, […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, keytruda, Lung Cancer, News, nivolumab, nsclc, opdivo, Precision Cancer Medicine